Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM)

J. Brož, D. Janíčková Žďárská, J. Urbanová, M. Brabec, V. Doničová, R. Štěpánová, E. Martinka, M. Kvapil,

. 2018 ; 9 (5) : 1897-1906. [pub] 20180809

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18034299

INTRODUCTION: The aim of the study was to determine the level of metabolic control in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients in the Czech and Slovak Republics. METHODS: A non-interventional prospective (observational) study was conducted from January 2015 until April 2016 in routine clinical practice settings at 141 centers in the Czech and Slovak Republics. Data were analyzed from a total of 425 patients with T1DM and 1034 patients with T2DM, proportionally corresponding to the number of patients in both countries. The primary objective of the study was to determine the percentage of patients with HbA1c < 7% (53 mmol/mol). RESULTS: Patients with T1DM: In this group of patients (55.8% males, mean age 45.9 ± 14.83 years, BMI 25.8 ± 4.21 kg/m², diabetes duration 12.1 ± 9.44 years), 29.9% reached HbA1c levels < 53 mmol/mol. Patients with T2DM: In this group of patients (50.3% male, mean age 63.9 ± 9.65 years, BMI 31.0 ± 5.19 kg/m², diabetes duration 12.4 ± 7.47 years, duration of insulin therapy 5.8 ± 4.71 years), 33.4% reached HbA1c levels < 53 mmol/mol. CONCLUSION: The overall percentage of patients with HbA1c < 53 mmol/mol in the T1DM group was 29.9% and in the T2DM group was 33.4%. Despite an increasing number of treatment options, most patients still fail to reach the recommended HbA1c targets. FUNDING: Sanofi, Czech Republic.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18034299
003      
CZ-PrNML
005      
20181026103325.0
007      
ta
008      
181008s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13300-018-0485-2 $2 doi
035    __
$a (PubMed)30094784
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brož, Jan $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic. zorb@seznam.cz.
245    10
$a Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM) / $c J. Brož, D. Janíčková Žďárská, J. Urbanová, M. Brabec, V. Doničová, R. Štěpánová, E. Martinka, M. Kvapil,
520    9_
$a INTRODUCTION: The aim of the study was to determine the level of metabolic control in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients in the Czech and Slovak Republics. METHODS: A non-interventional prospective (observational) study was conducted from January 2015 until April 2016 in routine clinical practice settings at 141 centers in the Czech and Slovak Republics. Data were analyzed from a total of 425 patients with T1DM and 1034 patients with T2DM, proportionally corresponding to the number of patients in both countries. The primary objective of the study was to determine the percentage of patients with HbA1c < 7% (53 mmol/mol). RESULTS: Patients with T1DM: In this group of patients (55.8% males, mean age 45.9 ± 14.83 years, BMI 25.8 ± 4.21 kg/m², diabetes duration 12.1 ± 9.44 years), 29.9% reached HbA1c levels < 53 mmol/mol. Patients with T2DM: In this group of patients (50.3% male, mean age 63.9 ± 9.65 years, BMI 31.0 ± 5.19 kg/m², diabetes duration 12.4 ± 7.47 years, duration of insulin therapy 5.8 ± 4.71 years), 33.4% reached HbA1c levels < 53 mmol/mol. CONCLUSION: The overall percentage of patients with HbA1c < 53 mmol/mol in the T1DM group was 29.9% and in the T2DM group was 33.4%. Despite an increasing number of treatment options, most patients still fail to reach the recommended HbA1c targets. FUNDING: Sanofi, Czech Republic.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janíčková Žďárská, Denisa $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic.
700    1_
$a Urbanová, Jana $u Center for Research in Diabetes, Metabolism and Nutrition, 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Brabec, Marek $u Institute of Computer Science of the ASCR, v.v.i., Prague, Czech Republic. Czech Institute of Informatics, Robotics, and Cybernetics, Czech Technical in University, Prague, Czech Republic.
700    1_
$a Doničová, Viera $u Private Department of Diabetology Internal Medicine and Metabolism, Kosice, Slovakia.
700    1_
$a Štěpánová, Radka $u Aprova sro, Brno, Czech Republic.
700    1_
$a Martinka, Emil $u National Institute of Endocrinology and Diabetology, Lubochna, Slovakia.
700    1_
$a Kvapil, Milan $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Prague, Czech Republic.
773    0_
$w MED00194311 $t Diabetes therapy research, treatment and education of diabetes and related disorders $x 1869-6953 $g Roč. 9, č. 5 (2018), s. 1897-1906
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30094784 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026103836 $b ABA008
999    __
$a ind $b bmc $g 1339749 $s 1031293
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c 5 $d 1897-1906 $e 20180809 $i 1869-6953 $m Diabetes therapy $n Diabetes Ther $x MED00194311
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options